GLP-1 Weight Loss Fort Lauderdale · Medical Weight Management
If you're researching GLP-1 Weight Loss Fort Lauderdale options, the goal shouldn't be finding a shortcut or choosing a medication based on social media. At Fusion Wellness Center, medical weight management begins with your health history, goals, medications, metabolic concerns, previous weight loss experience, and an individualized clinical evaluation. When appropriate, FDA-approved semaglutide- or tirzepatide-based treatment may be discussed as part of a broader physician-guided plan.
GLP-1 Weight Loss Fort Lauderdale: What Patients Should Know
GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone involved in appetite, digestion, glucose regulation, and metabolic signaling.
Certain prescription medications act on the GLP-1 receptor and are FDA approved for specific medical indications. Semaglutide is a GLP-1 receptor agonist, while tirzepatide activates both GLP-1 and GIP receptors.
These medications can be powerful tools for appropriate patients, but they are not interchangeable, appropriate for everyone, or a substitute for individualized medical care.
Quick clarity: There is no universal “best” GLP-1 weight loss medication. Semaglutide and tirzepatide have different mechanisms, approved products, dosing considerations, evidence, risks, and patient factors. The right choice depends on the individual.
What Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist. Different semaglutide products are FDA approved for different indications.
Wegovy is the semaglutide brand specifically approved for chronic weight management in qualifying patients, in combination with reduced-calorie nutrition and increased physical activity. Semaglutide is also sold under other brand names for different indications, so the product and indication matter.
In the landmark STEP 1 obesity trial, adults without diabetes receiving semaglutide 2.4 mg plus lifestyle intervention experienced an average body-weight reduction of approximately 14.9% at 68 weeks, compared with approximately 2.4% with placebo.
Individual results vary, and clinical trial averages should not be interpreted as a guarantee of an individual patient's outcome.
What Is Tirzepatide?
Tirzepatide acts on two metabolic hormone receptors: GIP and GLP-1.
Zepbound is the tirzepatide brand FDA approved for chronic weight management in qualifying adults. Tirzepatide is also marketed as Mounjaro for type 2 diabetes, which is a different FDA-approved indication.
In obesity clinical trials, tirzepatide has produced substantial average weight reductions when used with lifestyle intervention. As with semaglutide, however, patient response, tolerability, contraindications, adherence, dosing, and other factors vary.
Semaglutide vs. Tirzepatide: What's the Difference?
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Primary Mechanism | GLP-1 receptor agonist | GIP + GLP-1 receptor agonist |
| Weight Management Brand | Wegovy | Zepbound |
| Administration | Typically once-weekly injection for injectable Wegovy formulations | Once-weekly injection |
| Common Considerations | Medical history, tolerability, contraindications, response, access and individual goals | Medical history, tolerability, contraindications, response, access and individual goals |
| Which Is Better? | There is no universally best option. Treatment should be selected based on the individual patient. | |
What Does the Head-to-Head Research Show?
A 2025 randomized clinical trial directly compared tirzepatide with semaglutide in adults with obesity who did not have type 2 diabetes.
At 72 weeks, average weight reduction was approximately 20.2% with tirzepatide and 13.7% with semaglutide in that specific study population.
Those results are useful clinical information, but they do not mean every patient should automatically choose tirzepatide. A clinical trial compares population averages. Individual treatment decisions also need to consider safety, tolerability, medical history, contraindications, access, prior response, goals, and patient preference.
Who May Be a Candidate for GLP-1 Weight Management?
FDA-approved weight management medications have specific indications. For example, current approved indications commonly involve adults with obesity or certain adults with overweight who also have at least one weight-related condition.
Patients who contact Fusion for GLP-1 weight management often tell us they are dealing with:
- Difficulty losing weight despite lifestyle changes
- Weight regain after previous progress
- Persistent hunger or appetite-management challenges
- Metabolic health concerns
- Previous experience with weight management medication
- A desire for physician-guided care rather than a one-size-fits-all online program
Having one of these concerns does not automatically mean you are a candidate for medication. Eligibility depends on the specific drug, FDA-approved indication, medical history, medications, contraindications, and provider evaluation.
What to Expect at Fusion Wellness Center
1. Consultation & Eligibility Review
Your first visit begins with your individual situation. Our team reviews your goals, health history, current medications, previous weight-management efforts, and relevant health concerns.
2. Metabolic & Clinical Evaluation
Depending on your health and goals, your provider may recommend laboratory testing, metabolic evaluation, body composition assessment, or other information to help guide treatment.
3. Personalized Treatment Discussion
If prescription weight management medication is medically appropriate, your provider can discuss available options, including the potential role of semaglutide- or tirzepatide-based treatment.
If you want to learn more specifically about tirzepatide, visit our Tirzepatide Fort Lauderdale educational guide .
4. Sustainable Weight Management Strategy
Medication is one potential tool. A long-term plan may also address nutrition, physical activity, sleep, muscle preservation, metabolic health, behavior, stress, and other factors that affect weight and overall health.
Learn more about Fusion's physician-led medical weight management approach .
5. Ongoing Monitoring
Follow-up matters. Your clinical team monitors response, tolerability, side effects, progress, and whether treatment adjustments may be appropriate over time.
What Side Effects Can Occur With GLP-1-Based Medications?
Gastrointestinal symptoms are among the most common side effects associated with semaglutide and tirzepatide. Depending on the medication and patient, these can include nausea, vomiting, diarrhea, constipation, abdominal discomfort, or other symptoms.
FDA-approved prescribing information also contains important warnings, contraindications, precautions, and drug-specific considerations that should be reviewed by a qualified provider.
Why Medical Screening Matters
GLP-1-related medications are not appropriate for everyone. Medical history involving certain endocrine conditions, gastrointestinal disease, pancreatitis, gallbladder problems, kidney issues, pregnancy, medication interactions, or other factors may affect whether treatment is appropriate.
Never begin, stop, combine, or change the dose of a prescription weight management medication without guidance from the healthcare provider responsible for your treatment.
Is Medication Enough on Its Own?
Long-term weight management is about more than suppressing appetite.
For many patients, preserving lean muscle, supporting adequate protein intake, addressing metabolic health, improving sleep, maintaining physical activity, and developing sustainable habits are just as important as the medication itself.
That is why Fusion approaches GLP-1 weight management as part of a larger health strategy rather than simply providing a prescription and sending patients home.
Considering Semaglutide or Tirzepatide?
Start with an individualized medical conversation. Fusion Wellness Center can review your goals, medical history, current medications, and available options to determine whether a GLP-1-based weight management plan may be appropriate for you.
Book a Free Consultation →Prefer to talk first? Call (954) 368-8489
Frequently Asked Questions About GLP-1 Weight Loss Fort Lauderdale
No. Semaglutide primarily activates the GLP-1 receptor, while tirzepatide activates both GIP and GLP-1 receptors. They are different medications with different FDA-approved products, prescribing information, and clinical considerations.
Wegovy and Ozempic both contain semaglutide, but they are FDA-approved products with different indications and dosing. Wegovy is specifically approved for weight management and other indicated uses, while Ozempic has different approved indications. The brand and approved indication matter.
Both contain tirzepatide, but they have different FDA-approved indications. Zepbound is approved for chronic weight management in qualifying patients, while Mounjaro is approved for glycemic control in adults with type 2 diabetes.
In a 2025 head-to-head trial involving adults with obesity without type 2 diabetes, average weight reduction at 72 weeks was greater with tirzepatide than semaglutide. That population-level result does not determine which medication is appropriate for an individual patient.
Results vary significantly. Weight change generally develops over time rather than overnight, and medication doses are often increased gradually according to prescribing guidance and patient tolerability. Your provider can help set realistic expectations based on the treatment being considered.
Yes. Prescription weight management treatment requires appropriate medical evaluation. Your provider needs to review your health history, medications, contraindications, goals, and the specific treatment being considered.
Weight regain can occur after weight-management medication is discontinued. Obesity is a chronic condition, and long-term management may involve ongoing nutrition, physical activity, behavioral strategies, medical monitoring, and, for some patients, continued pharmacologic treatment. Your provider should help you plan for long-term management rather than focusing only on short-term weight loss.
Medical Sources & Further Reading
- U.S. Food & Drug Administration — Semaglutide / Wegovy Weight Management Information
- U.S. Food & Drug Administration — Tirzepatide / Zepbound for Chronic Weight Management
- New England Journal of Medicine — Semaglutide in Adults With Overweight or Obesity
- New England Journal of Medicine — Tirzepatide Compared With Semaglutide for Obesity
Take the Next Step Toward Your Weight Management Goals
Whether you're specifically researching semaglutide, tirzepatide, or simply want to understand your medical weight management options, Fusion Wellness Center can help you start with a personalized, physician-guided evaluation.
Book a Free Consultation →Call (954) 368-8489
